Daiichi Sankyo's Phase 1 study of milademetan in combination with quizartinib targets FLT3-ITD mutant AML, a significant segment of the leukemia market. The combination therapy aims to enhance efficacy over monotherapy, potentially positioning Daiichi Sankyo favorably against competitors in the AML treatment landscape. However, the study was terminated based on a business decision, which raises concerns regarding the commercial viability and future investment in this asset. The termination may reflect strategic realignment or challenges in achieving desired clinical outcomes, necessitating careful diligence for stakeholders considering involvement in this therapeutic area.